deCODE will apply its expertise in in vitro pharmacogenomics to provide gene expression data in relation to a Wyeth candidate treatment for respiratory disease
Reykjavik, ICELAND, November 20, 2002 — deCODE genetics (Nasdaq/Nasdaq Europe:DCGN) today announced the signing of a pharmacogenomics agreement with Wyeth (NYSE:WYE). As part of an observational study on the treatment of respiratory disease, deCODE will use its expertise in in vitro pharmacogenomics to generate gene expression data related to one of Wyeth’s candidate drugs.
Work under the collaboration will be carried out by Encode, deCODE’s wholly-owned pharmacogenomics and clinical trials subsidiary. For this study, Encode will isolate peripheral blood mononuclear cells from patients and generate gene expression profiles of cells through in vitro exposure to the candidate drug. Identifying gene expression patterns in relation to the compound could facilitate the selection of the most appropriate patient cohorts for clinical development. Additional details of the study and financial terms were not disclosed.
“We are pleased to be applying our expertise in in vitro pharmacogenomics to assist Wyeth in the development of new treatment for respiratory disease,” said Dr. Kari Stefansson, CEO of deCODE. “Wyeth is itself a pioneer in the use of pharmacogenomics. Therefore this collaboration represents a major validation of the value of our technology in this field.”
deCODE is using population genetics to create a new paradigm for healthcare. With its uniquely comprehensive population data, deCODE is turning research on the genetic causes of common diseases into a growing range of products and services — in gene and drug discovery, DNA-based diagnostics, pharmacogenomics, bioinformatics, and clinical trials. deCODE’s pharmaceuticals group, based in Chicago, and deCODE’s biostructures group, based in Seattle, conduct downstream development work on targets derived from deCODE’s proprietary research in human genetics as well as contract service work for pharmaceutical and biotechnology companies. deCODE is delivering on the promise of the new genetics.SM Visit us on the web at www.decode.com.
Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, integration of acquired businesses, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in deCODE’s filings with the Securities and Exchange Commission. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.